Retatrutide cost: no price yet, and what the legal routes cost

What will retatrutide cost? Right now, nothing you can legally pay for, because it has no price. Retatrutide is not approved by the FDA or any other regulator, and it can't legally be sold for human use [Lilly, Oct 28, 2026]. Lilly hasn't set a retatrutide cost, and says it will price the drug only after the trials and the regulatory review are done [Lilly, Oct 2026].

So this page can't give you a figure, and it won't guess one. What it can give you: what the two legal routes cost today, and dated prices for the approved drugs people compare retatrutide with. It also covers how insurance, Medicare and Medicaid treat weight-loss drugs now. Every price below was read on the maker's or the government's own page on Nov 12, 2026.

How much does retatrutide cost?

There is no retatrutide price. Lilly's answer to that exact question:

Upon completion of clinical trials and the regulatory review process, we plan to ensure retatrutide is priced to reflect the overall value to the healthcare system. Our goal is to make our medicines available and accessible to people who need them.

That's from Lilly's retatrutide page, last updated October 2026 [Lilly, Oct 2026]. Lilly hasn't filed for approval yet. It plans to apply to the FDA in Q1 2027 [Lilly, Sep 29, 2026], and the retatrutide FDA approval guide explains how long a review can take.

Any "retatrutide price" you see online is therefore not a Lilly price. Lilly says that Anyone purporting to sell retatrutide to consumers is breaking the law. [Lilly, Oct 28, 2026] We don't print prices for those products. The guide to retatrutide for sale explains what they are and what tests of them found.

What does it cost to get retatrutide legally today?

There are two legal routes, and neither one involves buying the drug.

A clinical trial. Lilly says that for most clinical trials, the investigational medicine is provided, and visits are conducted at no cost to the volunteer. Some trials also pay or reimburse volunteers, and you learn about any costs or payments during informed consent [Lilly Trials, Nov 2026]. If you have Medicare, Parts A and B cover some trial costs, such as office visits and tests, and you may pay 20% of the Medicare-approved amount [Medicare.gov trials, Nov 12, 2026]. Travel and time off are your own costs unless the study covers them. The one recruiting Lilly retatrutide trial is in fatty liver disease, and people in it may get tirzepatide or a placebo instead [ClinicalTrials.gov, NCT07165028].

Lilly's expanded access program. Lilly supplies retatrutide at no cost through the program [Lilly Medical, Aug 26, 2026]. Other costs can still apply. The FDA warns that insurers usually don't cover costs tied to investigational products. It adds that costs could be incurred related to IRB review, which may be your responsibility [FDA, Oct 29, 2026]. The program is narrow. It covers adults with a BMI of 35 or more despite the top available dose of a weight-management medicine, plus at least two serious complications. Their doctor has to apply for them [ClinicalTrials.gov, NCT07629401].

What do approved weight-loss drugs cost right now?

Retatrutide doesn't have a price, but the drugs it's compared with do. These are reference points only. They are not substitutes for retatrutide, not a guide to its future price, and not advice to switch. Each needs a prescription.

Two kinds of price matter. The list price, also called the wholesale acquisition cost, is what the maker charges wholesalers before discounts [Lilly pricing, Nov 12, 2026]. The self-pay price is what the maker charges a cash-paying patient through its own pharmacy program. Prices below are per month, as each maker defines a month.

Offers change the picture. Lilly offers $449 a month on the 7.5 to 15 mg Zepbound KwikPen if each refill is bought within 45 days of the last [Zepbound site, Nov 12, 2026]. New Wegovy pen patients pay $199 a month for two fills of the starting doses, an offer that runs through Dec 31, 2026 [NovoCare, Nov 12, 2026]. Foundayo's 2.5 mg and 5.5 mg tablets are temporarily cut to $149 and $199 through the same date [Foundayo site, Nov 12, 2026]. With commercial insurance that covers the drug, the makers' savings cards can bring Zepbound or Wegovy down to as little as $25 a month, within monthly limits [Zepbound site, Nov 12, 2026] [NovoCare, Nov 12, 2026].

The government's TrumpRx site lists the same self-pay starting points: Wegovy pill $149, Wegovy pen $199 and Zepbound $299 a month. It shows original prices of $1,349 for Wegovy and $1,087 for Zepbound [TrumpRx, Nov 12, 2026]. For how tirzepatide compares with retatrutide in the trials, see retatrutide vs tirzepatide.

Do the federal pricing deals apply to new drugs?

Partly, on paper. In November 2025, the White House announced a deal with Lilly and Novo Nordisk. It says both companies will guarantee MFN prices on all new medicines that they bring to market [White House, Nov 6, 2025]. MFN, or most-favored-nation, refers to matching the lowest price paid in other developed countries [White House, Nov 6, 2025].

Retatrutide would be a new Lilly medicine, but the fact sheet doesn't name it or set any price for it. Its $150 starting-dose promise covers pipeline drugs intended to be taken orally rather than as a shot [White House, Nov 6, 2025]. Retatrutide is a weekly injection in trials [Lilly, Oct 2026], so that line doesn't describe it. How the deal would apply to retatrutide is something only Lilly and the government can answer.

Will insurance cover retatrutide?

Not today. Retatrutide isn't on the market, and the FDA says insurers and Medicare usually don't cover the costs of investigational products [FDA, Oct 29, 2026]. What we can describe is how coverage works for approved weight-loss drugs on Nov 12, 2026, and what would have to happen for retatrutide.

Employer and private plans

Coverage depends on your plan. Lilly says all three of the largest pharmacy benefit managers now cover its obesity medicines [Lilly, May 28, 2026]. That's a company claim, and it doesn't mean every employer plan built on them does. Ask your plan whether it covers anti-obesity drugs at all.

Medicare

Federal law lets Medicaid exclude Agents when used for anorexia, weight loss, or weight gain [42 U.S.C. 1396r-8]. Medicare's Part D drug benefit borrows that list, so drugs used for weight loss sit outside the normal Part D definition [42 U.S.C. 1395w-102].

A temporary program fills part of the gap. Since Jul 1, 2026, the Medicare GLP-1 Bridge has covered Foundayo, Wegovy and the Zepbound KwikPen for eligible people with Part D, for a $50 monthly copayment [Medicare.gov, Nov 12, 2026]. You need to be 18 or older with a BMI of 35 or more, or a lower BMI with certain conditions. People with type 2 diabetes, sleep apnea or fatty liver disease aren't eligible, though their regular Part D plan might cover a GLP-1 [Medicare.gov, Nov 12, 2026]. The Bridge has been extended through Dec 31, 2027 [CMS, Sep 29, 2026]. Retatrutide isn't on its list.

Medicaid

The same law lets each state decide whether its Medicaid program covers weight-loss drugs [42 U.S.C. 1396r-8]. CMS's BALANCE model has CMS negotiate prices and coverage terms with makers on behalf of the states that join. States can join from May 2026 through Jan 1, 2027, and the model will not guarantee coverage for any individual [CMS, Sep 29, 2026].

Retatrutide can't be part of this round. Eligible drugs must be approved, or expected to be approved, for weight management by Jan 1, 2027 [CMS, Sep 29, 2026]. Lilly doesn't plan to file until Q1 2027 [Lilly, Sep 29, 2026]. CMS says it expects to renew negotiations as new drugs reach the market [CMS, Sep 29, 2026].

What would have to change

First, the FDA would have to approve retatrutide, and Lilly would have to set a price. After that, each plan decides. The Part D exclusion is written around a drug's medical uses, so a use other than weight loss can be treated differently [42 U.S.C. 1395w-102]. Lilly says its data support registrations for obesity, sleep apnea and knee osteoarthritis pain [Lilly, Aug 5, 2026]. How Medicare would treat each of those uses is our reading of the rules, not a coverage decision.

What's the retatrutide cost per month?

No honest figure exists. A monthly cost needs three things, and retatrutide has none of them yet: an approved product, an approved dose and a price. The trials tested several weekly doses, but a trial dose isn't a product anyone can buy.

Estimates you see online are guesses based on other drugs, or prices for products sold illegally. Neither tells you what Lilly will charge. When a price exists, it will appear on Lilly's own pages, and this page will be updated with the date.